Shri Thanedar sold Coherus BioSciences Inc (NASDAQ: CHRS)
Shri Thanedar (D-MI), a U.S. Representative, has disclosed 1 trade in Coherus BioSciences Inc (CHRS) since 2023, a single sale, worth an estimated $33K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Shri Thanedar sold $15,001 - $50,000 of Coherus BioSciences Inc (NASDAQ: CHRS) on January 23, 2023. Since that trade, CHRS is down -83.99% against the S&P 500 up +93.12%, an outperformance of -177.11%.
Data updated
Shri Thanedar's CHRS trades vs the price
CHRS is down -83.99% since Shri Thanedar sold on January 23, 2023, versus +93.12% for the S&P 500.
Performance since this trade
All Shri Thanedar CHRS trades
Shri Thanedar & CHRS trading FAQ
Is it legal for Shri Thanedar to trade Coherus BioSciences Inc (CHRS) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Coherus BioSciences Inc (CHRS), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Shri Thanedar sell CHRS?
Shri Thanedar disclosed a sale of $15,001 - $50,000 of Coherus BioSciences Inc (CHRS) on January 23, 2023, according to public STOCK Act filings.
How has CHRS performed since Shri Thanedar's trade?
Since Shri Thanedar sold CHRS on January 23, 2023, the stock is down -83.99%, versus +93.12% for the S&P 500 over the same period, an outperformance of -177.11%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional CHRS trades?
Quantellect tracks every disclosed congressional trade in Coherus BioSciences Inc (CHRS) on the Coherus BioSciences Inc congressional trading page, which aggregates filings across all members of Congress.
Shri Thanedar's CHRS tradesAll congressional filings for Coherus BioSciences IncShri Thanedar's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.